Bruce Booth
CIK 1451612 · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KYMR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 320
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 475,805 | $104.78 | $49.85M | -$263.36M | 27 | 2026-07-02 |
| SION | Director | 2,360,156 | $3.89 | $9.18M | -$21.01M | 8 | 2026-06-18 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | Director | 0 | $8.05 | $0 | $7.49M | 11 | 2025-08-05 |
| Tectonic Therapeutic, Inc. (AVRO) Delisted | Director | 463,941 | $16.80 | $7.79M | $15.00M | 7 | 2023-06-08 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 257,320 | $11.19 | $2.88M | $9.75M | 7 | 2022-06-30 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | 3,184,446 | — | — | $1.13M | 12 | 2020-07-06 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | 209,505 | — | — | $3.00M | 5 | 2018-06-28 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Director | 386,502 | — | — | $0 | 7 | 2018-01-05 |
Recent Filings · Page 3 of 9
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-16 | SION | Grant (A) | — | $0 | EDGAR |
| 2025-05-23 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2025-03-04 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-10 | SION | Mixed | +3,694,020 | $1.08M | EDGAR |
| 2024-07-09 | KYMR | Sell (S) | −453,960 | -$17.35M | EDGAR |
| 2024-06-20 | KYMR | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | KYMR | Sell (S) | −26,940 | -$950.2K | EDGAR |
| 2024-06-07 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-07 | Vigil Neuroscience, Inc. (VIGL) Delisted | Mixed | — | $0 | EDGAR |
| 2024-03-15 | KYMR | Sell (S) | −127,543 | -$5.13M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.